These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8084615)

  • 1. Specific DNA binding by p53 is independent of mutation at serine 389, the casein kinase II site.
    Rolley N; Milner J
    Oncogene; 1994 Oct; 9(10):3067-70. PubMed ID: 8084615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel system to investigate the phosphorylation of the p53 tumor suppressor protein by the protein kinase CK2.
    McKendrick L; Meek DW
    Cell Mol Biol Res; 1994; 40(5-6):555-61. PubMed ID: 7735330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site.
    Blaydes JP; Hupp TR
    Oncogene; 1998 Aug; 17(8):1045-52. PubMed ID: 9747884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
    Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
    Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory beta-subunit of protein kinase CK2.
    Appel K; Wagner P; Boldyreff B; Issinger OG; Montenarh M
    Oncogene; 1995 Nov; 11(10):1971-8. PubMed ID: 7478515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation.
    Mayr GA; Reed M; Wang P; Wang Y; Schweds JF; Tegtmeyer P
    Cancer Res; 1995 Jun; 55(11):2410-7. PubMed ID: 7757994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of RNA to p53 regulates its oligomerization and DNA-binding activity.
    Yoshida Y; Izumi H; Torigoe T; Ishiguchi H; Yoshida T; Itoh H; Kohno K
    Oncogene; 2004 May; 23(25):4371-9. PubMed ID: 15064727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single serine residue at position 375 of VP16 is critical for complex assembly with Oct-1 and HCF and is a target of phosphorylation by casein kinase II.
    O'Reilly D; Hanscombe O; O'Hare P
    EMBO J; 1997 May; 16(9):2420-30. PubMed ID: 9171355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53.
    Sugikawa E; Yazaki N; Tsunoda S; Nakanishi N; Ohashi M
    Biochem Biophys Res Commun; 1999 Aug; 261(2):256-63. PubMed ID: 10425175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of protein kinase activities associated with p53-large-T immune complexes from SV40-transformed rat cells.
    Müller E; Boldyreff B; Scheidtmann KH
    Oncogene; 1993 Aug; 8(8):2193-205. PubMed ID: 8393163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro.
    Cuddihy AR; Wong AH; Tam NW; Li S; Koromilas AE
    Oncogene; 1999 Apr; 18(17):2690-702. PubMed ID: 10348343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential.
    Mundt M; Hupp T; Fritsche M; Merkle C; Hansen S; Lane D; Groner B
    Oncogene; 1997 Jul; 15(2):237-44. PubMed ID: 9244359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression.
    Fiscella M; Ullrich SJ; Zambrano N; Shields MT; Lin D; Lees-Miller SP; Anderson CW; Mercer WE; Appella E
    Oncogene; 1993 Jun; 8(6):1519-28. PubMed ID: 8502477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.
    Fiscella M; Zambrano N; Ullrich SJ; Unger T; Lin D; Cho B; Mercer WE; Anderson CW; Appella E
    Oncogene; 1994 Nov; 9(11):3249-57. PubMed ID: 7936649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity.
    Unger T; Sionov RV; Moallem E; Yee CL; Howley PM; Oren M; Haupt Y
    Oncogene; 1999 May; 18(21):3205-12. PubMed ID: 10359526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate.
    Milne DM; McKendrick L; Jardine LJ; Deacon E; Lord JM; Meek DW
    Oncogene; 1996 Jul; 13(1):205-11. PubMed ID: 8700548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nuclear serine/threonine protein kinase DNA-PK.
    Anderson CW; Lees-Miller SP
    Crit Rev Eukaryot Gene Expr; 1992; 2(4):283-314. PubMed ID: 1486241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
    Hansen S; Lane DP; Midgley CA
    J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage.
    Jimenez GS; Bryntesson F; Torres-Arzayus MI; Priestley A; Beeche M; Saito S; Sakaguchi K; Appella E; Jeggo PA; Taccioli GE; Wahl GM; Hubank M
    Nature; 1999 Jul; 400(6739):81-3. PubMed ID: 10403253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme.
    Milne DM; Palmer RH; Campbell DG; Meek DW
    Oncogene; 1992 Jul; 7(7):1361-9. PubMed ID: 1620549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.